UK Medicine Supply Chain on Edge: Iran Conflict Sparks Shortage Fears
Britain could face medicine shortages “within weeks” if the ongoing conflict in Iran continues to disrupt global supply chains, experts warn. From essential painkillers to critical cancer treatments, the availability of numerous medications is under threat, alongside potential price increases. The crisis stems from disruptions to vital raw materials and transportation networks, impacting the pharmaceutical industry at multiple levels.
The Perfect Storm: Geopolitical Tensions and Supply Chain Vulnerabilities
The current situation represents a confluence of challenging factors. The conflict in the Gulf has led to the near total closure of the Strait of Hormuz, a critical shipping lane. Simultaneously, India, often referred to as the “pharmacy of the world” and a major producer of generic drugs and active pharmaceutical ingredients (APIs), faces increased logistical hurdles. David Weeks, director of supply chain risk management at Moody’s, describes it as “the perfect storm.”
Air and Sea Routes Disrupted, Costs Soar
Pharmaceutical shipments are facing significant delays. Initially closed, airports in Dubai, Doha and Abu Dhabi are now operating on limited schedules, forcing companies to reroute flights. This shift to air transport, coupled with the strain on sea routes through the Strait of Hormuz, is driving up costs. The US-Israel war on Iran has already doubled air freight costs, impacting approximately one in five NHS medicines transported by air.
Although sea transport remains the primary method for most medicines, the need to circumvent the Strait of Hormuz adds approximately 14 days to journeys and an additional $1 million (£750,000) in fuel costs per shipment.
Generics and NHS Impact: A Delicate Balance
The majority of medications used by the National Health Service (NHS) – around 85% – are generic drugs. Mark Samuels, chief executive of Medicines UK, notes that while a crisis hasn’t yet materialized, the situation is serious. Medical distributors typically maintain six to eight weeks of stock, with hospitals required to hold eight weeks’ worth, but these buffers could be quickly depleted if the conflict persists.
Manufacturers of generic drugs operate on historically low margins, making them particularly vulnerable to increased transportation costs. While long-term pricing agreements exist with NHS hospitals, suppliers have more flexibility to raise prices for drugs supplied to GP practices and pharmacies.
Beyond Transportation: The Ripple Effect on Raw Materials
The impact extends beyond transportation. Rising crude oil and natural gas prices are increasing the cost of petrochemical products like methanol and ethylene, essential components in the manufacturing of APIs, syringes, vials, and other medical supplies. This broadens the scope of potential price increases and supply chain disruptions.
Prioritizing Healthcare Cargo, But at What Cost?
Experts anticipate that healthcare cargo will be prioritized over other goods, such as e-commerce shipments, when capacity is limited. However, the overall cost increases will likely be passed on to patients, either directly or through public health systems like the NHS.
What Does the Future Hold?
The duration of the conflict is the key determinant of the severity of the impact. Wouter Dewulf, a professor at the Antwerp Management School, suggests that drugmakers may implement single-digit price increases if the situation worsens. Frank Van Gelder, a healthcare and pharma supply chain strategist, highlights the significant disruption to the Middle East airspace corridor, which previously handled approximately 3,700 passenger flights carrying cargo daily. Air cargo levels have already dropped by 80%.
FAQ: Medicine Shortages and the Iran Conflict
- Could I experience difficulty getting my prescription filled? It’s possible, particularly for medications sourced from or transported through the affected regions.
- Will the NHS be able to cope with increased costs? The NHS is facing financial pressures, and increased drug costs will add to these challenges.
- Are all medicines equally at risk? Medicines requiring rapid air transport – such as cancer treatments, infectious disease therapies, and cell/gene therapies – are most vulnerable.
- What is being done to mitigate the risks? Pharmaceutical companies are exploring alternative transportation routes and suppliers, but these solutions reach with increased costs.
Pro Tip: If you rely on a specific medication, discuss potential alternatives with your doctor or pharmacist as a precautionary measure.
Did you know? India produces 60% of the generic medicines used globally and half of the US requirements.
Stay informed about the evolving situation and its potential impact on healthcare. Explore our other articles on global supply chain challenges and healthcare policy for further insights.
